FIELD: organic chemistry, medicine, oncology, pharmacology.
SUBSTANCE: invention relates to a composition used in treatment of proliferative diseases and comprising the platinum coordinating complex with an anti-tumor agent and derivative of pentafluorobenzene sulfonamide. Also, invention relates to a method for treatment by using the indicated composition. The composition possesses the synergetic effect.
EFFECT: improved and valuable method of therapy.
13 cl, 5 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATING AND ANTIPROLIFERATIVE AGENTS | 2003 |
|
RU2386625C2 |
| NEW CHEMICAL COMPOUNDS (VERSIONS) AND USING THEM FOR TREATING ONCOLOGICAL DISEASES | 2013 |
|
RU2550346C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2010 |
|
RU2577700C2 |
| PLATINUM NANOCOMPOUNDS AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2538199C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
| CXCR7 INHIBITORS FOR CANCER TREATMENT | 2019 |
|
RU2808667C2 |
| HYDROXAMATE DERIVATIVES SUITABLE AS DEACETYLASE INHIBITORS | 2001 |
|
RU2302408C2 |
